Hepatitis vaccines are essential tools in preventing viral infections that target the liver, specifically Hepatitis A and Hepatitis B. The Hepatitis A vaccine is vital for safeguarding against contamination-related infections, commonly transmitted through contaminated food or water. It is particularly recommended for travelers to regions with a higher prevalence of Hepatitis A. The Hepatitis B vaccine is a key component in preventing chronic Hepatitis B infections, which can lead to severe liver diseases, including cirrhosis and liver cancer. Administered as part of routine childhood immunization schedules, it is also recommended for adults, especially those at an increased risk of exposure. Combined vaccines, such as the Hepatitis A and B combination, provide comprehensive protection against both viruses. Beyond individual protection, widespread vaccination efforts contribute significantly to public health by reducing the overall burden of Hepatitis-related diseases globally. Continuous research and development efforts aim to expand vaccine coverage, addressing additional Hepatitis strains and reinforcing the commitment to preventing and controlling Hepatitis infections on a global scale. Regular vaccination campaigns and healthcare initiatives remain critical in promoting broad immunization against Hepatitis.
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Recombinant BCG vaccine as a potent anti tuberculosis vaccine candidate
Sajal Dey, BRIC-Centre for DNA Fingerprinting and Diagnostics, India
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : Advancing vaccine availability and equity in low-resource settings: Evidence from Awendo Sub-County, Kenya
Millicent Ochieng, Clinton Health Access Initiative, Kenya
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : From local pilots to national policy: Key issues and challenges in implementing nationwide HPV vaccination in China
Shenglan Tang, Duke Global Health Institute, United States